目的 观察通脉养心丸联合酒石酸美托洛尔片治疗冠心病室性早搏的临床疗效。方法 选择2013年7月—2014年6月济南市第三人民医院收治的冠心病患者110例，随机分为对照组（54例）和治疗组（56例）。在常规治疗基础上，对照组口服酒石酸美托洛尔片，25 mg/次，2次/d。治疗组患者在对照组治疗基础上口服通脉养心丸，40粒/次，2次/d。两组均连续治疗4周。对患者治疗前后的平均心室率、动态心电图及临床疗效进行比较。结果 治疗后，治疗组的平均心室率低于对照组，但差异无统计学意义；对照组和治疗组室性早搏数目减少的总有效率分别为72.2%、91.1%，治疗组显著优于对照组，且差异有统计学意义（P<0.05）；对照组和治疗组临床疗效的总有效率分别为74.0%、89.3%，治疗组显著优于对照组，且差异具有统计学意义（P<0.05）。结论 通脉养心丸联合酒石酸美托洛尔片可明显减少室性早搏的发作，并能够有效改善患者症状，提高生存质量。

Objective To evaluate the clinical efficacy of Tongmai Yangxin Pills combined with Metoprolol Tartrate Tablets in the treatment of coronary heart disease and ventricular premature contractions (VPCs). Methods The patients with coronary heart disease (110 cases) in the Third Hospital of Jinan from July 2013 to June 2014 were randomly divided into control (n = 54) and treatment (n = 56) groups. The patients in the control group were po administered with Metoprolol Tartrate Tablets on the basis of conventional treatment, 25 mg/time, twice daily. The patients in the treatment group were po administered with Tongmai Yangxin Pills on the basis of the control group, 40 granules/time, twice daily. The patients in the two groups were treated continuously for 4 weeks. After the treatment, the average ventricular rate, dynamic electrocardiogram, and clinical efficacy in the two groups were compared. Results After the treatment, the average ventricular rate in the treatment group was lower than that in the control group, while there was no significant differenve between the two groups. The total effective rates of VPCs decrease in the treatment and control groups were 72.2% and 91.1%, respectively. The treatment group was much better than the control group, and there was significant difference between the two groups (P < 0.05). The total effective rates of clinical efficacy in the treatment and control groups were 74.0% and 89.3%, respectively. The treatment group was much better than the control group with significant difference (P < 0.05). Conclusion Tongmai Yangxin Pills combined with Metoprolol Tartrate Tablets can significantly reduce the break of ventricular premature beat. effectively improve the symptoms of the patients, and promote the quality of life.